ERBB2 and sarcoma: Accordingly, it has been shown that the transferrin receptor 1 (TfR1) and the epidermal growth factor receptors 1 and 2 (EGFR1, Her2) are overexpressed in early and advanced sarcoma [6,7,8], thus representing potential targets of interest in IT-based sarcoma therapy.